Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.

@article{Takehana2002StatusOC,
  title={Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.},
  author={Takuo Takehana and Kazuyoshi Kunitomo and Koji Kono and Fumiaki Kitahara and Hidehiko Iizuka and Yoshiro Matsumoto and Masayuki A. Fujino and Akishi Ooi},
  journal={International journal of cancer},
  year={2002},
  volume={98 6},
  pages={833-7}
}
c-erb-2 amplification and overexpression are currently attracting a great deal of attention because a new adjuvant therapy using an antibody against the c-erbB-2 gene product, trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), has proved effective in treating breast cancer with amplification and/or overexpression of c-erbB-2. Aberrations of c-erbB-2 have also been detected in ovarian, endometrial and gastric carcinomas at varied frequencies. Amplification of the c-erbB-2 locus… CONTINUE READING